NfL neurofilament light
Selected indexed studies
- Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. (EBioMedicine, 2024) [PMID:38354532]
- Neurofilaments as biomarkers in neurological disorders - towards clinical application. (Nat Rev Neurol, 2024) [PMID:38609644]
- Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome. (EBioMedicine, 2024) [PMID:38518653]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. (2024) pubmed
- Neurofilaments as biomarkers in neurological disorders - towards clinical application. (2024) pubmed
- Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome. (2024) pubmed
- Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus. (2023) pubmed
- Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. (2023) pubmed
- Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. (2020) pubmed
- Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. (2022) pubmed
- Neurofilaments and Neurofilament Proteins in Health and Disease. (2017) pubmed
- Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. (2023) pubmed
- Neurofilament Light Protein Rod Domain Exhibits Structural Heterogeneity. (2024) pubmed